Report date: Nov 6,2024
Conflict count: 361874
Publisher: SAGE Publications
Title count: 532
Conflict count: 30231


==========================================================

Created: 2017-01-12 06:09:06
ConfID: 5188291
CauseID: 1400444683
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Tran,6,2,64,2000,The impact of introducing pre-printed chemotherapy medication charts to a day chemotherapy unit
DOI: 10.1191/107815500678816179(Journal) (5188291-N)
DOI: 10.1177/107815520000600206(Journal)
==========================================================

Created: 2017-01-12 06:09:06
ConfID: 5188290
CauseID: 1400444683
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Roscoe,6,2,60,2000,A multidisciplinary approach to ensure safety in the prescribing and administration of chemotherapy
DOI: 10.1191/107815500678816197(Journal) (5188290-N)
DOI: 10.1177/107815520000600205(Journal)
==========================================================

Created: 2017-01-12 06:09:06
ConfID: 5188289
CauseID: 1400444683
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Poole,6,2,55,2000,Establishing a baseline incidence of adverse drug reactions in hospitalised oncology patients
DOI: 10.1191/107815500678816160(Journal) (5188289-N)
DOI: 10.1177/107815520000600204(Journal)
==========================================================

Created: 2017-01-12 06:09:06
ConfID: 5188288
CauseID: 1400444683
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Dooley,6,2,50,2000,Reproducibility of treatment methodologies detailed in contemporary clinical trial reports
DOI: 10.1191/107815500678816188(Journal) (5188288-N)
DOI: 10.1177/107815520000600203(Journal)
==========================================================

Created: 2017-01-12 06:09:06
ConfID: 5188287
CauseID: 1400444683
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Kolesar,6,2,43,2000,Docetaxel in hepatic impairment
DOI: 10.1191/107815500678816214(Journal) (5188287-N)
DOI: 10.1177/107815520000600202(Journal)
==========================================================

Created: 2017-01-12 06:09:06
ConfID: 5188286
CauseID: 1400444683
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Dranitsaris,6,2,37,2000,The cost of blood transfusions in cancer patients: a reanalysis of a Canadian economic evaluation
DOI: 10.1191/107815500678816205(Journal) (5188286-N)
DOI: 10.1177/107815520000600201(Journal)
==========================================================

Created: 2017-01-12 06:12:04
ConfID: 5188419
CauseID: 1400445875
OtherID: 183022205
JT: Journal of Oncology Pharmacy Practice
MD: ,10,2,61,2004,Abstracts
DOI: 10.1191/1078155204jp121oa(Journal) (5188419-N)
DOI: 10.1177/107815520401000201(Journal)
==========================================================

Created: 2017-01-12 06:14:10
ConfID: 5188476
CauseID: 1400446752
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Hole,5,4,194,1999,Audit of efficacy of 3 mg versus 1 mg of intravenous granisetron as antiemetic prophylaxis against acute emesis caused by cisplatin or melphalan
DOI: 10.1191/107815599678840516(Journal) (5188476-N)
DOI: 10.1177/107815529900500406(Journal)
==========================================================

Created: 2017-01-12 06:14:10
ConfID: 5188475
CauseID: 1400446752
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Spina,5,4,190,1999,A retrospective review of gemcitabine use in advanced epithelial ovarian cancer
DOI: 10.1191/107815599678840507(Journal) (5188475-N)
DOI: 10.1177/107815529900500405(Journal)
==========================================================

Created: 2017-01-12 06:14:10
ConfID: 5188474
CauseID: 1400446752
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: McLennan,5,4,184,1999,Beneficial clinical outcomes resulting from pharmacist interventions
DOI: 10.1191/107815599678840471(Journal) (5188474-N)
DOI: 10.1177/107815529900500404(Journal)
==========================================================

Created: 2017-01-12 06:14:10
ConfID: 5188473
CauseID: 1400446752
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Kapelushnik,5,4,179,1999,Thalidomide does not interfere with graft-versus-leukemia reactivity in mice
DOI: 10.1191/107815599678840499(Journal) (5188473-N)
DOI: 10.1177/107815529900500403(Journal)
==========================================================

Created: 2017-01-12 06:14:10
ConfID: 5188471
CauseID: 1400446752
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: van Gijn,5,4,166,1999,Protein kinase C as a target for new anti-cancer agents
DOI: 10.1191/107815599678840525(Journal) (5188471-N)
DOI: 10.1177/107815529900500402(Journal)
==========================================================

Created: 2017-01-12 06:15:56
ConfID: 5188491
CauseID: 1400447230
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: ,6,1,3,2000,The Seventh International Symposium on Oncology Pharmacy Practice
DOI: 10.1191/107815500678827375(Journal) (5188491-N)
DOI: 10.1177/107815520000600101(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188623
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Adams,5,3,117,1999,Oprelvekin (Neumega®)
DOI: 10.1191/107815599678840390(Journal) (5188623-N)
DOI: 10.1177/107815529900500302(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188622
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Dopp,5,3,109,1999,Risk of breast cancer associated with hormone replacement therapy
DOI: 10.1191/107815599678840417(Journal) (5188622-N)
DOI: 10.1177/107815529900500301(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188630
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Sewell,5,3,143,1999,Oncology pharmacy in the new millennium
DOI: 10.1191/107815599678840462(Journal) (5188630-N)
DOI: 10.1177/107815529900500309(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188629
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Goffredo,5,3,140,1999,The role of the oncology pharmacist in 1999
DOI: 10.1191/107815599678840453(Journal) (5188629-N)
DOI: 10.1177/107815529900500308(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188628
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: ,5,3,139,1999,Reports from the Second Pan-European Oncology Hospital Pharmacy Symposium
DOI: 10.1191/107815599678840444(Journal) (5188628-N)
DOI: 10.1177/107815529900500307(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188627
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Wiedemann,5,3,135,1999,Year 2000 guidelines for the use of antimicrobial agents in adult and pediatric neutropenic patients with unexplained fever from the Universities of Lübeck and Kiel
DOI: 10.1191/107815599678840435(Journal) (5188627-N)
DOI: 10.1177/107815529900500306(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188626
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Bakhshandeh,5,3,131,1999,Year 2000 guidelines for clinical practice of whole body hyperthermia combined with cytotoxic drugs from the University of Lübeck and the University of Wisconsin
DOI: 10.1191/107815599678840426(Journal) (5188626-N)
DOI: 10.1177/107815529900500305(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188625
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Paull,5,3,128,1999,Antiemetic guidelines: Royal North Shore Hospital
DOI: 10.1191/107815599678840381(Journal) (5188625-N)
DOI: 10.1177/107815529900500304(Journal)
==========================================================

Created: 2017-01-12 06:19:33
ConfID: 5188624
CauseID: 1400448659
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Junker,5,3,125,1999,Antiemetic guidelines: A cooperation between a non-university hospital (Klinikum Remscheid) and a university center (Medical University of Lübeck) in Germany
DOI: 10.1191/107815599678840408(Journal) (5188624-N)
DOI: 10.1177/107815529900500303(Journal)
==========================================================

Created: 2017-01-12 06:28:11
ConfID: 5189031
CauseID: 1400451641
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Wong,5,1,49,1999,Clinical pharmacy services in oncology clinics
DOI: 10.1191/107815599678847104(Journal) (5189031-N)
DOI: 10.1177/107815529900500104(Journal)
==========================================================

Created: 2017-01-12 06:28:11
ConfID: 5189030
CauseID: 1400451641
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Medina,5,1,32,1999,Treatment of hormone-refractory prostate cancer
DOI: 10.1191/107815599678847131(Journal) (5189030-N)
DOI: 10.1177/107815529900500103(Journal)
==========================================================

Created: 2017-01-12 06:28:11
ConfID: 5189029
CauseID: 1400451641
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Fjornes,5,1,22,1999,Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia
DOI: 10.1191/107815599678847122(Journal) (5189029-N)
DOI: 10.1177/107815529900500102(Journal)
==========================================================

Created: 2017-01-12 06:28:11
ConfID: 5189028
CauseID: 1400451641
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Smith,5,1,7,1999,Cancer gene therapy update
DOI: 10.1191/107815599678847113(Journal) (5189028-N)
DOI: 10.1177/107815529900500101(Journal)
==========================================================

Created: 2017-01-12 06:28:29
ConfID: 5189049
CauseID: 1400451797
OtherID: 684713074
JT: Journal of Oncology Pharmacy Practice
MD: ,14,4,233,2008,Erratum
DOI: 10.1177/1078155208098835(Journal) (5189049-N)
DOI: 10.1177/1078155208098836(Journal)
==========================================================

Created: 2017-01-12 06:34:27
ConfID: 5189215
CauseID: 1400453150
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Gilbar,6,3,81,2000,The role of octreotide in symptom management in oncology and palliative care
DOI: 10.1191/107815500701563308(Journal) (5189215-N)
DOI: 10.1177/107815520000600302(Journal)
==========================================================

Created: 2017-01-12 06:34:27
ConfID: 5189219
CauseID: 1400453150
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Harrison,6,3,122,2000,Docetaxel-induced extravasation injury: a report of three cases
DOI: 10.1191/107815500701563344(Journal) (5189219-N)
DOI: 10.1177/107815520000600306(Journal)
==========================================================

Created: 2017-01-12 06:34:27
ConfID: 5189218
CauseID: 1400453150
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Thiesen,6,3,115,2000,Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags
DOI: 10.1191/107815500701563335(Journal) (5189218-N)
DOI: 10.1177/107815520000600305(Journal)
==========================================================

Created: 2017-01-12 06:34:27
ConfID: 5189217
CauseID: 1400453150
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Connor,6,3,109,2000,The effect of isopropyl alcohol on the permeation of gloves exposed to antineoplastic agents
DOI: 10.1191/107815500701563326(Journal) (5189217-N)
DOI: 10.1177/107815520000600304(Journal)
==========================================================

Created: 2017-01-12 06:34:27
ConfID: 5189216
CauseID: 1400453150
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: van Gijn,6,3,92,2000,Dual topoisomerase I/II inhibitors
DOI: 10.1191/107815500701563317(Journal) (5189216-N)
DOI: 10.1177/107815520000600303(Journal)
==========================================================

Created: 2017-01-12 06:35:30
ConfID: 5189270
CauseID: 1400453368
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Cabelguenne,5,2,87,1999,Impact of centralization of cytotoxic drug preparations
DOI: 10.1191/107815599678847177(Journal) (5189270-N)
DOI: 10.1177/107815529900500205(Journal)
==========================================================

Created: 2017-01-12 06:35:30
ConfID: 5189269
CauseID: 1400453368
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Krämer,5,2,75,1999,Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices
DOI: 10.1191/107815599678847168(Journal) (5189269-N)
DOI: 10.1177/107815529900500203(Journal)
==========================================================

Created: 2017-01-12 06:35:30
ConfID: 5189268
CauseID: 1400453368
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Krug,5,2,67,1999,The K-port concept: Proposal for optimising a fully implantable port system
DOI: 10.1191/107815599678847186(Journal) (5189268-N)
DOI: 10.1177/107815529900500202(Journal)
==========================================================

Created: 2017-01-12 06:35:30
ConfID: 5189267
CauseID: 1400453368
OtherID: 10901856
JT: Journal of Oncology Pharmacy Practice
MD: Harrison,5,2,61,1999,Penetration and splash protection of six disposable gown materials against fifteen antineoplastic drugs
DOI: 10.1191/107815599678847159(Journal) (5189267-N)
DOI: 10.1177/107815529900500201(Journal)
==========================================================

Created: 2017-06-29 17:46:22
ConfID: 5258009
CauseID: 1408154158
OtherID: 103673404
JT: Journal of Oncology Pharmacy Practice
MD: ,10,3,187,2004,Erratum
DOI: 10.1191/1078155204jp133xx(Journal) (5258009-N)
DOI: 10.1177/107815520401000309(Journal)